235 related articles for article (PubMed ID: 21371540)
1. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth.
Ghosh I; Bose S; Vippagunta R; Harmon F
Int J Pharm; 2011 May; 409(1-2):260-8. PubMed ID: 21371540
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of vitamin E TPGS/HPMC supersaturated system and other solubilizer/polymer combinations to enhance the permeability of a poorly soluble drug through the skin.
Ghosh I; Michniak-Kohn B
Drug Dev Ind Pharm; 2012 Nov; 38(11):1408-16. PubMed ID: 22296239
[TBL] [Abstract][Full Text] [Related]
3. Design and characterization of submicron formulation for a poorly soluble drug: the effect of Vitamin E TPGS and other solubilizers on skin permeability enhancement.
Ghosh I; Michniak-Kohn B
Int J Pharm; 2012 Sep; 434(1-2):90-8. PubMed ID: 22633930
[TBL] [Abstract][Full Text] [Related]
4. Optimization of formulation and process parameters for the production of nanosuspension by wet media milling technique: effect of Vitamin E TPGS and nanocrystal particle size on oral absorption.
Ghosh I; Schenck D; Bose S; Ruegger C
Eur J Pharm Sci; 2012 Nov; 47(4):718-28. PubMed ID: 22940548
[TBL] [Abstract][Full Text] [Related]
5. Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability.
Yang H; Teng F; Wang P; Tian B; Lin X; Hu X; Zhang L; Zhang K; Zhang Y; Tang X
Int J Pharm; 2014 Dec; 477(1-2):88-95. PubMed ID: 25455766
[TBL] [Abstract][Full Text] [Related]
6. Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology.
George M; Ghosh I
Eur J Pharm Sci; 2013 Jan; 48(1-2):142-52. PubMed ID: 23085547
[TBL] [Abstract][Full Text] [Related]
7. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
8. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer.
Gao Y; Li Z; Sun M; Li H; Guo C; Cui J; Li A; Cao F; Xi Y; Lou H; Zhai G
Drug Dev Ind Pharm; 2010 Oct; 36(10):1225-34. PubMed ID: 20545506
[TBL] [Abstract][Full Text] [Related]
9. Development of novel polymer-stabilized diosmin nanosuspensions: in vitro appraisal and ex vivo permeation.
Freag MS; Elnaggar YS; Abdallah OY
Int J Pharm; 2013 Sep; 454(1):462-71. PubMed ID: 23830765
[TBL] [Abstract][Full Text] [Related]
10. Supersaturatable formulations for the enhanced oral absorption of sirolimus.
Kim MS; Kim JS; Cho W; Cha KH; Park HJ; Park J; Hwang SJ
Int J Pharm; 2013 Mar; 445(1-2):108-16. PubMed ID: 23396259
[TBL] [Abstract][Full Text] [Related]
11. Fabrication and evaluation of celecoxib microparticle surface modified by hydrophilic cellulose and surfactant.
Ha ES; Ok J; Noh J; Jeong HY; Choo GH; Jung YS; Baek IH; Kim JS; Cho W; Hwang SJ; Kim MS
Int J Biol Macromol; 2015 Jan; 72():1473-8. PubMed ID: 25451745
[TBL] [Abstract][Full Text] [Related]
12. An Extrusion Spheronization Approach to Enable a High Drug Load Formulation of a Poorly Soluble Drug with a Low Melting Surfactant.
Tatavarti A; Kesisoglou F
J Pharm Sci; 2015 Nov; 104(11):3752-3759. PubMed ID: 26205160
[TBL] [Abstract][Full Text] [Related]
13. D-Alpha-tocopherol acid polyethylene glycol 1000 succinate, an effective stabilizer during solidification transformation of baicalin nanosuspensions.
Yue PF; Wan J; Wang Y; Li Y; Ma YQ; Yang M; Hu PY; Yuan HL; Wang CH
Int J Pharm; 2013 Feb; 443(1-2):279-87. PubMed ID: 23291447
[TBL] [Abstract][Full Text] [Related]
14. Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physiochemical properties and low oral bioavailability.
Singh MK; Pooja D; Ravuri HG; Gunukula A; Kulhari H; Sistla R
Phytomedicine; 2018 Feb; 40():48-54. PubMed ID: 29496174
[TBL] [Abstract][Full Text] [Related]
15. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
[TBL] [Abstract][Full Text] [Related]
16. Nanosuspensions of a poorly soluble investigational molecule ODM-106: Impact of milling bead diameter and stabilizer concentration.
Singhal M; Baumgartner A; Turunen E; van Veen B; Hirvonen J; Peltonen L
Int J Pharm; 2020 Sep; 587():119636. PubMed ID: 32659405
[TBL] [Abstract][Full Text] [Related]
17. Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation.
Dong Y; Ng WK; Shen S; Kim S; Tan RB
Int J Pharm; 2009 Jun; 375(1-2):84-8. PubMed ID: 19481693
[TBL] [Abstract][Full Text] [Related]
18. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
[TBL] [Abstract][Full Text] [Related]
19. Formulation and drying of miconazole and itraconazole nanosuspensions.
Cerdeira AM; Mazzotti M; Gander B
Int J Pharm; 2013 Feb; 443(1-2):209-20. PubMed ID: 23291552
[TBL] [Abstract][Full Text] [Related]
20. Optimization of Hydroxypropyl Methylcellulose and Dextrin in Development of Dried Nanosuspension for Poorly Water-Soluble Drug.
Heo EJ; Park SY; Kim HI; Sung JH; Kwon HJ; Jee JP; Maeng HJ; Cho KH; Kim ST; Kim YC; Choi SU; Jang DJ
J Nanosci Nanotechnol; 2020 Sep; 20(9):5813-5818. PubMed ID: 32331187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
